



Figure S1: Post-antibiotic effect of test compounds. (A) *S. aureus* ATCC 29213 against TM-02, (B) *S. aureus* ATCC 29213 against TM-03, (C) *E. coli* MC4100 against TM-02 and (D) *E. coli* MC4100 against TM-03. Concentrations used range from no antibiotic (blue), 0.5 x MIC (orange), 1 x MIC (green) to 4 x MIC (purple). Results are reported as the time it took to increase the bacterial count by 1 log following T = 0 h.

Figure S2: Enantioselective synthesis of TM-02 and compound characterization.



N-formyl Tomatidine **1** was synthesized following literature reported by Chagnon *et al.* (<http://dx.doi.org/10.1016/j.ejmech.2013.11.019>)

Compound 2





N-formyl Tomatidine **1** (1.50 g, 3.38 mmol) was dissolved in dry tetrahydrofuran (58 mL, 57 mM) under Ar_(g) along with triphenylphosphine (1.77 g, 6.76 mmol) and 4-nitrobenzoic acid (1.58 g, 9.47 mmol). Diisopropyl-azodicarboxylate (1.35 mL, 6.76 mmol) was added and the reaction was stirred for 16h. The volatiles were removed under reduced pressure and the residue was suspended in water (50 mL) and extracted with ethyl acetate (3 x 70 mL). The combined organic phase was washed with brine (70 mL), dried over magnesium sulfate, and concentrated under reduced pressure. Purification by silica gel chromatography (20 to 60% AcOEt:Hex) afforded a white solid residue. The residue was dissolved in a 4:1 mixture of tetrahydrofuran: water (50 mL, 68 mM). Lithium hydroxide monohydrate (0.323 g, 13.5 mmol) was added at ambient temperature and the reaction was stirred for 16h. The reaction was diluted with ethyl acetate (120 mL) and the organic phase was washed with saturated ammonium chloride solution (80 mL), brine (80 mL), dried over magnesium sulfate and concentrated under reduced pressure. Purification by silica gel chromatography (30 to 75% AcOEt:Hex) yielded (3*R*)-N-formyl tomatidine **2** as a white solid (1.09 g, 73%).

¹H NMR (400 MHz, CDCl₃) δ (ppm) 8.41 (s, 1H), 4.32-4.24 (m, 1H), 4.17-4.09 (m, 1H), 4.06-4.00 (brs, 1H), 2.70-2.60 (m, 1H), 2.59-2.49 (m, 1H), 2.05-1.94 (m, 1H), 1.91-1.83 (m, 1H),


1.80-1.07 (m, 24H), 1.05 (d, 3H, $J = 6.9$ Hz), 0.90 (d, 3H, $J = 5.8$ Hz), 0.82 (s, 3H), 0.79 (s, 3H), 0.79-0.72 (m, 1H).

^{13}C NMR (101 MHz, CDCl_3) δ (ppm) 158.9 (CH), 97.8 (C_q), 78.6 (CH), 66.6 (CH), 62.5 (CH), 56.0 (CH), 54.4 (CH), 44.8 (CH_2), 41.4 (C_q), 40.4 (CH_2), 39.2 (CH), 37.0 (CH), 36.3 (C_q), 36.0 (CH_2), 35.1 (CH), 32.3 (CH_2), 32.2 (CH_2), 32.1 (CH_2), 30.9 (CH), 29.3 (CH_2), 29.1 (CH_2), 28.5 (CH_2), 27.7 (CH_2), 20.7 (CH_2), 19.1 (CH_3), 17.1 (CH_3), 15.4 (CH_3), 11.4 (CH_3).






Compound 3




(3*R*)-*N*-formyl Tomatidine **2** (0.995 g, 2.24 mmol) was dissolved in dry dichloromethane (45 mL, 50 mM) under $\text{Ar}_{(\text{g})}$. Triethylamine (0.469 mL, 3.36 mmol) and methanesulfonyl chloride (0.260 mL, 3.36 mmol) were added dropwise at ambient temperature and the mixture was stirred for 3h at ambient temperature. The reaction was quenched with saturated ammonium chloride solution (50 mL) and diluted with DCM (70 mL). The aqueous phase was extracted with DCM (3 x 50 mL) and the combined organic phase was washed with brine (80 mL), dried over magnesium sulfate, and concentrated under reduced pressure to afford a residue. The residue was dissolved in 1,3-dimethyl-3,4,5,6-tetrahydro-2-pyrimidinone (45 mL, 50 mM) under $\text{Ar}_{(\text{g})}$. Sodium azide (0.729 g, 11.2 mmol) was added at ambient temperature and the reaction was heated at 60°C for 16h. After cooling to ambient temperature, water (80 mL) was added, and the white suspension was filtered. The solid was collected and filtrate was extracted with diethyl ether (2 x 110 mL). The organic phase was dried over magnesium sulfate and concentrated under reduced pressure. Purification of the residue by silica gel chromatography (5 to 70% AcOEt:Hex) yielded compound **3** as a white solid (0.936 g, 89%).


^1H NMR (400 MHz, CDCl_3) δ (ppm) 8.41 (s, 1H), 4.34-4.23 (m, 1H), 4.18-4.09 (m, 1H), 3.25 (tt, 1H, $J = 4.6$ Hz, $J = 11.8$ Hz), 2.69-2.61 (m, 1H), 2.58-2.49 (m, 1H), 2.03-1.94 (m, 1H), 1.90-1.07 (m, 22H), 1.05 (d, 3H, $J = 6.9$ Hz), 1.02-0.84 (m, 2H), 0.91 (d, 3H, $J = 5.9$ Hz), 0.82 (brs, 6H), 0.66 (td, 1H, $J = 4.2$ Hz, $J = 12.1$ Hz).

^{13}C NMR (101 MHz, CDCl_3) δ (ppm) 158.9 (CH), 97.8 (C_q), 78.6 (CH), 62.5 (CH), 60.6 (CH), 55.9 (CH), 54.3 (CH), 45.3 (CH), 44.7 (CH₂), 41.4 (C_q), 40.3 (CH₂), 37.2 (CH₂), 36.9 (CH), 35.7 (C_q), 35.0 (CH), 34.1 (CH₂), 32.2 (CH₂), 32.1 (CH₂), 30.8 (CH), 29.3 (CH₂), 28.5 (CH₂), 27.7 (CH₂), 21.1 (CH₂), 19.1 (CH₃), 17.1 (CH₃), 15.4 (CH₃), 12.4 (CH₃).





Compound 4





Compound **3** (0.910 g, 1.94 mmol) was dissolved in dry ethyl acetate (45.0 mL, 43 mM) under Ar_(g). Palladium hydroxide, 20 wt. % Pd on carbon (0.136 g, 0.194 mmol) was added at ambient temperature. The mixture was degassed under sonication for 10 mins. Then, a balloon of hydrogen_(g) was plugged, and the solution was stirred for 16h. at ambient temperature. Upon full conversion, the flask was flushed with Ar_(g), the mixture diluted with ethyl acetate (80 mL) and the solution filtered on a pad of celite. The volatiles were removed under reduced pressure. Purification by silica gel chromatography (5 to 20% DCM:MeOH (10%NH₄OH)) yielded compound **4** as a white solid (0.509 g, 59%).

¹H NMR (400 MHz, CD₃OD) δ (ppm) 8.39 (s, 1H), 4.27-4.13 (m, 2H), 2.72-2.52 (m, 3H), 2.05-1.95 (m, 2H), 1.90-1.78 (m, 2H), 1.75-1.12 (m, 21H), 1.09 (d, 3H, *J* = 6.9 Hz), 1.06-0.94 (m, 2H), 0.92 (d, 3H, *J* = 5.9 Hz), 0.88 (s, 3H), 0.85 (s, 3H), 0.72 (td, 1H, *J* = 4.1 Hz, *J* = 12.2 Hz).


¹³C NMR (101 MHz, CD₃OD) δ (ppm) 160.8 (CH), 99.2 (C_q), 79.9 (CH), 63.9 (CH), 57.0 (CH), 55.8 (CH), 51.9 (CH), 46.9 (CH), 45.9 (CH₂), 42.5 (C_q), 41.3 (CH₂), 39.1 (CH₂), 38.8 (CH₂),

38.2 (CH), 36.8 (C_q), 36.5 (CH), 33.5 (CH₂), 33.0 (CH₂), 32.3 (CH₂), 32.0 (CH), 30.2 (CH₂), 29.8 (CH₂), 28.7 (CH₂), 22.2 (CH₂), 19.4 (CH₃), 17.4 (CH₃), 15.7 (CH₃), 12.8 (CH₃).



¹H NMR (400 MHz, CDCl₃) δ (ppm) 8.36 (s, 1H), 4.31-4.18 (m, 1H), 4.09 (dd, 1H, *J* = 7.1 Hz, *J* = 15.7 Hz), 2.72-2.56 (m, 2H), 2.55-2.38 (m, 2H), 1.99-1.90 (m, 1H), 1.87-1.78 (m, 1H), 1.77-1.00 (m, 24H), 1.01 (d, 3H, *J* = 6.9 Hz), 0.86 (d, 3H, *J* = 5.8 Hz), 0.78 (s, 3H), 0.76 (s, 3H), 0.61 (td, 1H, *J* = 3.9 Hz, *J* = 12.0 Hz).


¹³C NMR (101 MHz, CDCl₃) δ (ppm) 158.8 (CH), 97.7 (C_q), 78.5 (CH), 62.4 (CH), 55.9 (CH), 54.4 (CH), 51.1 (CH), 45.5 (CH), 44.7 (CH₂), 41.3 (C_q), 40.3 (CH₂), 37.5 (CH₂), 36.8 (CH), 35.7 (C_q), 35.0 (CH), 32.3 (CH₂), 32.1 (CH₂), 30.8 (CH), 29.2 (CH₂), 28.6 (CH₂), 27.6 (CH₂), 21.0 (CH₂), 19.0 (CH/CH₃), 17.0 (CH/CH₃), 15.3 (CH/CH₃), 12.4 (CH/CH₃).



filtered and purified by MS preparative HPLC (0.5% formic acid) to yield compound **TM-02** as a colorless solid (0.022g, 5%).

¹H NMR (400 MHz, CD₃OD) δ (ppm) 8.31 (s, 0.1 H, HCO₂H), 4.39 (dd, 1H, *J* = 7.3 Hz, *J* = 15.6 Hz), 3.28-3.23 (m, 3H), 3.16-3.06 (m, 2H), 2.91 (t, 1H, *J* = 12.3 Hz), 2.25-2.17 (m, 1H), 2.09-1.94 (m, 4H), 1.92-1.13 (m, 26H), 1.11 (d, 3H, *J* = 7.0 Hz), 0.98 (d, 3H, *J* = 6.5 Hz), 0.93 (s, 3H), 0.90 (s, 3H), 0.77 (td, 1H, *J* = 3.8 Hz, *J* = 12.1 Hz).

¹³C NMR (101 MHz, CD₃OD) δ (ppm) 97.6, 82.4, 63.1, 58.9, 56.8, 55.2, 49.3, 46.0, 43.1, 42.3, 42.2, 41.0, 37.6, 37.5, 36.8, 36.3, 33.2, 32.8, 32.5, 29.7, 29.5, 27.1, 27.0, 26.2, 22.1, 18.7, 17.3, 14.7, 12.5.



JD1-207-FA

